» Articles » PMID: 36910611

Association Between Metabolic Obesity Phenotypes and Multiple Myeloma Hospitalization Burden: A National Retrospective Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Mar 13
PMID 36910611
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Purpose: Obesity and metabolic disorders were associated with increased risk of MM, a disease characterized by high risk of relapsing and require frequent hospitalizations. In this study, we conducted a retrospective cohort study to explore the association of metabolic obesity phenotypes with the readmission risk of MM.

Patients & Methods: We analyzed 34,852 patients diagnosed with MM from the Nationwide Readmissions Database (NRD), a nationally representative database from US. Hospitalization diagnosis of patients were obtained using ICD-10 diagnosis codes. According to obesity and metabolic status, the population was divided into four phenotypes: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO). The patients with different phenotypes were observed for hospital readmission at days 30-day, 60-day, 90-day and 180-day. Multivariate cox regression model was used to estimate the relationship between obesity metabolic phenotypes and readmissions risk.

Results: There were 5,400 (15.5%), 7,255 (22.4%), 8,025 (27.0%) and 7,839 (35.6%) unplanned readmissions within 30-day, 60-day, 90-day and 180-day follow-up, respectively. For 90-day and 180-day follow-up, compared with patients with the MHNO phenotype, those with metabolic unhealthy phenotypes MUNO (90-day: P = 0.004; 180-day: P = < 0.001) and MUO (90-day: P = 0.049; 180-day: P = 0.004) showed higher risk of readmission, while patients with only obesity phenotypes MHO (90-day: P = 0.170; 180-day: P = 0.090) experienced no higher risk. However, similar associations were not observed for 30-day and 60-day. Further analysis in 90-day follow-up revealed that, readmission risk elevated with the increase of the combined factor numbers, with aHR of 1.068 (CI: 1.002-1.137, P = 0.043, with one metabolic risk factor), 1.109 (CI: 1.038-1.184, P = 0.002, with two metabolic risk factors) and 1.125 (95% CI: 1.04-1.216, P = 0.003, with three metabolic risk factors), respectively.

Conclusion: Metabolic disorders, rather than obesity, were independently associated with higher readmission risk in patients with MM, whereas the risk elevated with the increase of the number of combined metabolic factors. However, the effect of metabolic disorders on MM readmission seems to be time-dependent. For MM patient combined with metabolic disorders, more attention should be paid to advance directives to reduce readmission rate and hospitalization burden.

Citing Articles

Association of severe obesity with risk of conversion to open in laparoscopic cholecystectomy for acute cholecystitis.

Coaston T, Vadlakonda A, Curry J, Mallick S, Le N, Branche C Surg Open Sci. 2024; 20:1-6.

PMID: 38873329 PMC: 11166894. DOI: 10.1016/j.sopen.2024.05.005.


Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer.

Mohammed Ali Abed Al-Janabi A, Momeni H, Jasim Obaid Al-Harbi H Asian Pac J Cancer Prev. 2024; 25(5):1599-1605.

PMID: 38809631 PMC: 11318829. DOI: 10.31557/APJCP.2024.25.5.1599.

References
1.
Visade F, Babykina G, Puisieux F, Bloch F, Charpentier A, Delecluse C . Risk Factors for Hospital Readmission and Death After Discharge of Older Adults from Acute Geriatric Units: Taking the Rank of Admission into Account. Clin Interv Aging. 2021; 16:1931-1941. PMC: 8565893. DOI: 10.2147/CIA.S327486. View

2.
Nagy E, Cseh V, Barcs I, Ludwig E . The Impact of Comorbidities and Obesity on the Severity and Outcome of COVID-19 in Hospitalized Patients-A Retrospective Study in a Hungarian Hospital. Int J Environ Res Public Health. 2023; 20(2). PMC: 9859007. DOI: 10.3390/ijerph20021372. View

3.
Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer J . Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2019; 189(1):67-71. DOI: 10.1111/bjh.16292. View

4.
Westheim A, Bitorina A, Theys J, Shiri-Sverdlov R . COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. Obes Rev. 2021; 22(10):e13313. PMC: 8420274. DOI: 10.1111/obr.13313. View

5.
Tirado-Velez J, Benitez-Rondan A, Cozar-Castellano I, Medina F, Perdomo G . Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells. Ann Hematol. 2011; 91(1):83-8. DOI: 10.1007/s00277-011-1246-8. View